Scientists from the US Department of Energy and Stony Brook University have been selected to receive up to $1.4m in applied research funds from the Department of Defense to develop drugs that block the paralytic and deadly effects of neurotoxic poisons.

The funding from the Department of Defense Threat Reduction Agency (DTRA) will enable the Department of Energy’s Brookhaven National Laboratory and Stony Brook University’s Institute of Chemical Biology and Drug Discovery to develop the drugs, which could provide a important cure in the event of bioterrorism attacks.

Produced by clostridium botulinum bacteria, botulinum toxins are poisonous proteins that destroy vital muscle movement-controlling nerve cells components, preventing the muscles from functioning, which can lead to paralysis and death.

The drug development process will focus on, among other objectives, deciphering the structure of enzyme-inhibitor complexes, and screening large databases for candidate molecules and peptides blocking the active sites of multiple botulinum toxin strains.

The process will include developing a single drug to block the toxic effects of multiple strains, as there are seven different strains, or serotypes, of the botulinum toxin, including four that affect humans.

The current treatment for botulinum toxin exposure is only effective if administered before the toxin infiltrates target cells, a critical time period that may pass before a diagnosis is made.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.